Ipsen announced the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026, further to the vacancy of Mr. Henri Beaufour?s position. Peter Guenter holds nearly 40 years of experience as an executive leader in the global pharmaceutical industry. Most recently, he served as Chief Executive Officer of Merck Healthcare and member of the Executive Board of Merck Group from 2021 to 2025.
Prior to that, Peter was CEO at Almirall, where from 2017 onward, he led the company?s strategic refocus on medical dermatology. He also spent more than 20 years at Sanofi across numerous leadership roles and joined Sanofi's Executive Committee in 2013. Throughout his career, Peter has had a proven track record of success in partnerships, and excellence in execution.
Beyond these executive leadership roles, Peter is an active contributor to a variety of boards across the healthcare and private equity landscapes. Following this co-optation, Ipsen?s Board of Directors will remain composed of 14 directors: seven women and seven men, including five independent directors and two directors representing employees. At the next Shareholders?
meeting, there will be a request for ratification of this decision, which would remain in effect for the remainder of Henri Beaufour?s term of office, until the 2027 Shareholders? meeting.
